Tactic Pharma LLC - 24 Sep 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Reporting relationship: 10%+ Owner
Issuer ticker: MNPR
Reported as of: 24 Sep 2025
Net transaction value: -$34,999,957
SEC form: 4
Accepted by SEC: 26 Sep 2025, 15:53:30 UTC
Prior SEC filing: 04 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Chandler Robinson, Attorney-in-fact

Key filing fact

Tactic Pharma LLC filed Form 4 for Monopar Therapeutics (MNPR) on 26 Sep 2025.

Key facts

This page summarizes Tactic Pharma LLC's Form 4 filing for Monopar Therapeutics (MNPR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 26 Sep 2025, 15:53.

Change

Previous filing in this sequence was filed on 04 Apr 2025.
Current net transaction value: -$34,999,957.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (5)

CIK 0001727357 Primary reporting owner

Tactic Pharma LLC

Relationship: 10%+ Owner
Address: C/O 598 ROCKEFELLER RD, LAKE FOREST
Signature: /s/ Chandler Robinson, Attorney-in-fact
Signature date: 26 Sep 2025

CIK 0001727334

Robinson Chandler

Relationship: Chief Executive Officer, Director
Address: 1000 SKOKIE BLVD SUITE 350, WILMETTE
Signature: /s/ Chandler Robinson, Attorney-in-fact
Signature date: 26 Sep 2025

CIK 0001035909

Brown Michael J

Relationship: Member of 10% Owner Group
Address: C/O 598 ROCKEFELLER RD, LAKE FOREST
Signature: /s/ Chandler Robinson, Attorney-in-fact
Signature date: 26 Sep 2025

CIK 0001727481

O'Halloran Thomas V.

Relationship: Member of 10% Owner Group
Address: C/O 598 ROCKEFELLER RD, LAKE FOREST
Signature: /s/ Chandler Robinson, Attorney-in-fact
Signature date: 26 Sep 2025

CIK 0001727393

Mazar Andrew Paul

Relationship: Member of 10% Owner Group
Address: C/O 598 ROCKEFELLER RD, LAKE FOREST
Signature: /s/ Chandler Robinson, Attorney-in-fact
Signature date: 26 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MNPR transaction

Common Stock

Sale

Transaction value: $34,999,957
Shares: -550,229
Change %: -67%
Price: $63.61
Shares after: 272,026
Date: 24 Sep 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Tactic Pharma LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. The Reporting Persons are no longer subject to Section 16, except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics Inc.